3C
ESPR

361 Capital’s Esperion Therapeutics ESPR Stock Holding History

361 Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$920K Buy
+17,936
New +$750K 0.43% 59

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

361 Capital's ESPR Position: Q2 2020 in Review

361 Capital opened a new position in Esperion Therapeutics (ESPR) in Q2 2020: 17,936 shares worth $920K. The stake represents 0.43% of the portfolio and ranks #59 among its holdings.

182 funds tracked by Wall St. Rank hold ESPR as of Q2 2020.

  • 361 Capital held 17,936 shares of Esperion Therapeutics worth $920K as of Q2 2020.
  • Esperion Therapeutics was a new 361 Capital position in Q2 2020.
  • Esperion Therapeutics made up 0.43% of 361 Capital's portfolio in Q2 2020, its #59 holding.
  • 182 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.